Nalidixic Acid

Urinary Tract Infections
Treatment
7 Active Studies for Nalidixic Acid

What is Nalidixic Acid

Nalidixic acidThe Generic name of this drug
Treatment SummaryNalidixic acid is a synthetic drug used to kill bacteria. It works by preventing the bacteria’s DNA from being able to replicate, which stops the bacteria from growing and spreading. This drug is only effective against a limited number of bacteria.
NegGramis the brand name
image of different drug pills on a surface
Nalidixic Acid Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
NegGram
Nalidixic acid
1964
1

Effectiveness

How Nalidixic Acid Affects PatientsNalidixic acid is a type of antibiotic taken orally to treat infections caused by certain bacteria. It is especially effective against gram-negative bacteria such as Enterobacter, E. coli, Morganella Morganii, Proteus Mirabilis, Proteus vulgaris, and Providencia rettgeri. Pseudomonas species are usually resistant to this drug. Nalidixic acid is able to fight bacteria in any pH range in the urinary tract. In rare cases, resistance to nalidixic acid can develop within 2-14% of patients taking it in full dosage, but this resistance cannot be
How Nalidixic Acid works in the bodyNalidixic acid works by attaching to DNA in cells and blocking the production of RNA and proteins. This stops the cell from working properly.

When to interrupt dosage

The recommended measure of Nalidixic Acid is contingent upon the determined condition. The amount of dosage fluctuates, in regard to the technique of delivery (e.g. Tablet - Oral or Oral) as depicted in the table beneath.
Condition
Dosage
Administration
Urinary Tract Infections
500.0 mg,
, Oral, Tablet - Oral, Tablet

Warnings

Nalidixic Acid Contraindications
Condition
Risk Level
Notes
Porphyrias
Do Not Combine
Seizures
Do Not Combine
known hypersensitivity to the drug or any of the ingredients
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Nalidixic Acid.
Common Nalidixic Acid Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Amiodarone.
Amitriptyline
Major
Nalidixic acid may increase the QTc-prolonging activities of Amitriptyline.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Artemether.
Nalidixic Acid Toxicity & Overdose RiskThe lethal dose for rats is 1160mg/kg and for mice is 572mg/kg. Taking too much of this drug can cause mental confusion, seizures, increased pressure in the skull, or too much acid in the body. Overdosing can also lead to vomiting, nausea, and tiredness.
image of a doctor in a lab doing drug, clinical research

Nalidixic Acid Novel Uses: Which Conditions Have a Clinical Trial Featuring Nalidixic Acid?

10 active trials are currently assessing the efficacy of Nalidixic Acid in the treatment of Urinary Tract Infections.
Condition
Clinical Trials
Trial Phases
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4

Nalidixic Acid Reviews: What are patients saying about Nalidixic Acid?

3Patient Review
10/15/2011
Nalidixic Acid for Bacterial Urinary Tract Infection
This medication quickly and effectively took care of my UTI symptoms. Paired with the antibiotic, it cleared up the infection entirely.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nalidixic acid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is nalidixic acid still used?

"This medication was historically used to treat urinary tract infections that were caused by different types of bacteria. Now, there are other medications that are less toxic and more effective, so this drug is no longer used for that purpose in the USA."

Answered by AI

What does nalidixic acid prevent?

"Nalidixic acid was the first quinolone antibiotic to be approved, in 1963. Later quinolone antibiotics (and their derivative, fluoroquinolones) work by inhibiting DNA replication and repair. They do this by targeting DNA gyrase, an enzyme essential for these processes. These antibiotics are effective against both Gram-positive and Gram-negative bacteria."

Answered by AI

What class of drug is nalidixic acid?

"NegGram is a drug in the quinolone antibiotics class. It is not known if it is safe and effective in children."

Answered by AI

What are the side effects of nalidixic acid?

"and/or diarrhea

Drowsiness, weakness, headache, dizziness, spinning sensation (vertigo), abdominal pain, nausea, vomiting, and/or diarrhea can all be symptoms of a concussion."

Answered by AI

Clinical Trials for Nalidixic Acid

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX
Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. For our hypothesis, patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.
Waitlist Available
Has No Placebo
Baylor College of MedicineLarissa Grigoryan, MD, PhD
Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA
At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalAnna Binstock, MD
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Have you considered Nalidixic Acid clinical trials? We made a collection of clinical trials featuring Nalidixic Acid, we think they might fit your search criteria.Go to Trials
Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ
Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.
Recruiting
Has No Placebo
Atlantic Health
Image of Vriginia Mason Medical Center in Seattle, United States.

Antibiotic Usage for Overactive Bladder

18+
All Sexes
Seattle, WA
Intradetrusor injection of onabotulinumtoxinA, which is performed through a cystoscopic procedure, has been demonstrated to be efficacious in the treatment of both neurogenic and non-neurogenic overactive bladder (OAB), and is FDA approved as a treatment for overactive bladder. Intradetrusor of onabotulinumtoxinA is currently standard of care of patients with OAB who have persistent OAB symptoms despite behavioral therapies and oral medication treatments for OAB. As one of the main adverse events associated with intradetrusor injection of onabotulinumtoxinA is UTI, and published guidelines for cystoscopic procedures with manipulation recommend the use of prophylactic antibiotics, a single dose of prophylactic antibiotic is administered prior to this procedure. However, these recommendations are primarily based on data from randomized controlled trials (RCTs) involving antimicrobial prophylaxis during transurethral resection of the prostate. A previously published prospective study demonstrated that the rate of post-procedural UTI did not differ amongst patients with neurogenic bladder who did not receive prophylactic antibiotics and were asymptomatic for UTI, regardless of whether they had sterile urine cultures or asymptomatic bacteriuria, suggesting that patients who are not symptomatic for UTI may not require antibiotic prophylaxis prior to intradetrusor onabotulinumtoxinA injection. Studies have reported that up to 50% of antibiotic usage is inappropriate, leading to unnecessary exposure of patients to potential complications of antibiotic therapy, including Clostridium difficile infection which can cause recurrent diarrhea that may progress to sepsis and death, increasing antibiotic resistances, as well as dermal/allergic and gastro-intestinal manifestations. Therefore, in an effort to optimize antibiotic use, the investigators propose a prospective, randomized study to formally evaluate the differences in UTI frequency in subjects who have a negative urinalysis and are not symptomatic for UTI and receive prophylactic antibiotics at the time of intradetrusor onabotulinumtoxinA injection compared to those who do not receive prophylactic antibiotics at the time of injection. The proposed study seeks to evaluate the current practice standard of antibiotic prophylaxis prior to intradetrusor onabotulinumtoxin injection.
Recruiting
Has No Placebo
Vriginia Mason Medical Center (+1 Sites)Justina Tam, MD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security